Be0033 2

Manufactured by BioXCell

Sourced in Japan

The BE0033-2 is a laboratory equipment designed for general-purpose use. It serves as a device for performing various tasks required in a research or analytical setting. The core function of this product is to facilitate essential laboratory procedures, but a detailed description of its intended use is not available.

Automatically generated - may contain errors

Lab products found in correlation

Be0061, by BioXCell (1 mentions) Caerulein, by Merck Group (1 mentions) Gsk1120212, by Selleck Chemicals (1 mentions) Easysep magnetic kit, by STEMCELL (1 mentions) Cd3 28 magnetic dynabeads, by Thermo Fisher Scientific (1 mentions) Rpmi 1640 media, by Thermo Fisher Scientific (1 mentions) Mif00, by R&D Systems (1 mentions) Be0091, by BioXCell (1 mentions) Polyclonal armenian hamster igg, by BioXCell (1 mentions) C57bl 6j mice, by Charles River Laboratories (1 mentions) Lenvatinib, by Eisai (1 mentions)

5 protocols using be0033 2

Murine Pancreatic Cancer Induction and Treatment

Cited 4 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

To induce pancreatitis, mice aged 4–6 weeks were treated with 8-hourly intraperitoneal (i.p.) injections of caerulein (Sigma-Aldrich) at a dosage of 75 µg/kg body weight over 2 consecutive days. DT (Enzo Life Science) was administered i.p. every 4 days at a concentration of 25 ng/g. To establish the subcutaneous tumour model, 2×10⁶ of primary mouse pancreatic cancer cell lines iKras*1, iKras*2 and iKras*3 derived from iKras*p53* tumours,11 (link)
13 (link) 4×10⁵ of 65 671 cells (FVB/NJ strain)14 (link) or 7940B cells (C57BL/6J strain)15 (link) derived from KPC tumour (P48-Cre; loxP-stop-loxP (LSL)-Kras^G12D; p53^flox/+) were injected into CD11d-DTR mice of compatible genetic background. Tumour diameters were measured with digital callipers and the tumour volume was calculated by the formula: length×width²/2. For CD8⁺ T-cell depletion, anti-CD8 monoclonal antibody (BioXcell #BE0061; clone 2.43; 200 µg/mouse) was injected i.p. twice per week. Purified anti-mPD-1 antibody (BioXcell #BE0033-2; clone J43) was used for in vivo PD-1 blockade at a dose of 200 μg/i.p. injection, repeated every 3 days if needed. MEK inhibitor (MEKi) GSK1120212 (Selleckchem) was administered daily (1 mg/kg, i.p.) in a 10% (2-Hydroxypropyl)-β-cyclodextrin solution.

Zhang Y., Velez-Delgado A., Mathew E., Li D., Mendez F.M., Flannagan K., Rhim A.D., Simeone D.M., Beatty G.L, & Pasca di Magliano M. (2016). Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer. Gut, 66(1), 124-136.

+ Open protocol

+ Expand

Evaluating PD-1 Blockade and NextA in Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

SM1 melanoma cells were cultured in a six-well plate to form a monolayer to 70% confluency. Splenocytes from C57BL/6 mice were harvested and homogenized. CD3+ cells were isolated by EasySep magnetic kit (StemCell, 19851 A) through negative selection. Cells were checked for viability to > 85%. CD3+ splenocytes then were stimulated with CD3/28 magnetic dynabeads (Thermo Fisher Scientific, 11456D) overnight in complete RPMI 1640 media (Gibco, 11875101). The stimulated T cells were then layered onto the SM1-monolayer for 24 hours. Anti-PD1 antibody (BioXCell, BE0033-2) was then added to the culture at a final concentration of 1ug/ml and cultured for another 24 hours. Anti-mouse IFNγ antibody (PBL Assay Science, 22500-1, rabbit serum;) was then added to the culture at two different dilutions of 1:100 and 1:1000 relative to the total volume of culture media. In a separate well, NextA was added to a final concentration of 2.5 and 5 μM. Cells and supernatant were collected after 24 hours of incubation for detection of PD-L1 expression (Qiagen, 74104) and secreted levels of IFNγ by ELISA (R&D Systems, MIF00).

Knox T., Sahakian E., Banik D., Hadley M., Palmer E., Noonepalle S., Kim J., Powers J., Gracia-Hernandez M., Oliveira V., Cheng F., Chen J., Barinka C., Pinilla-Ibarz J., Lee N.H., Kozikowski A, & Villagra A. (2019). Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells. Scientific Reports, 9, 6136.

+ Open protocol

+ Expand

Preclinical evaluation of TH-Z827 and anti-PD-1 in PDAC

Check if the same lab product or an alternative is used in the 5 most similar protocols

BALB/c nude mice were subcutaneously injected with Panc 04.03 cells (1 × 10⁷ per dose) at Day 0. Mice were randomized when the mean tumor volume was ~70 mm³. Each group of mice (n = 10) was intraperitoneally injected with PBS, 10 mg/kg or 30 mg/kg TH-Z827 according to the dosage schedule from Day 38 to Day 62.
C57BL/6 mice were subcutaneously injected with KPC (KrasLSL.G12D/ + ; p53R172H/+; PdxCretg/+) cells (5 × 10⁵ per dose). Mice were randomized when the mean tumor volume was ~20 mm³. Mice of each group (n = 10) were intraperitoneally injected with PBS, anti-PD-1 antibody (100 μg per dose, Bio X Cell, BE0033-2), 10 mg/kg TH-Z827, or a combination (10 mg/kg TH-Z827 and anti-PD-1 antibody) according to a pre-defined dosage schedule from Day 7 to Day 38. Polyclonal Armenian hamster IgG (Bio X Cell, BE0091) was used as a control antibody.
Statistical analysis of differences in mean tumor volume between vehicle and treated groups were assessed using one-way ANOVA test conducted in GraphPad Prism. P value < 0.05 was considered statistically significant.

Mao Z., Xiao H., Shen P., Yang Y., Xue J., Yang Y., Shang Y., Zhang L., Li X., Zhang Y., Du Y., Chen C.C., Guo R.T, & Zhang Y. (2022). KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge. Cell Discovery, 8, 5.

+ Open protocol

+ Expand

Subcutaneous tumor mouse model

Check if the same lab product or an alternative is used in the 5 most similar protocols

When MC38 cells grew reaching about 80% confluence, they were harvested and washed three times in phosphate-buffered saline (PBS). 5.0 × 10⁵ cells were inoculated subcutaneously into the right flank of each mouse. Tumor volume and mouse weights were monitored every 3 days. Tumor volume was calculated as length × width² × 0.5. The survival status of these mice was checked and recorded every day. For anti-PD-1 treatment, mice were intraperitoneally injected with anti-PD-1 (J43, BE0033-2, BioXcell) at a dose of 200 μg/mouse every 3 days for three times.

Zhang S.L., Han B., Mao Y.Q., Zhang Z.Y., Li Z.M., Kong C.Y., Wu Y., Chen G.Q, & Wang L.S. (2022). Lacticaseibacillus paracasei sh2020 induced antitumor immunity and synergized with anti-programmed cell death 1 to reduce tumor burden in mice. Gut Microbes, 14(1), 2046246.

+ Open protocol

+ Expand

Syngeneic HCC mouse models for immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

Two subcutaneous syngeneic HCC models were generated by injecting 5x10 6 Hepa1-6 cells (ATCC) in 100 μl PBS in 5-6-week old female C57BL/6J mice (Charles River Laboratories)
(n = 59) and 5x10 6 Hep53.4 cells (CLS) in 5-6-week old male C57BL/6J mice (n = 40) 14 .
Animals were weighed and tumor volume was assessed 3 times per week. Once tumors reached 200 mm 3 , animals were randomly assigned to receive lenvatinib (Eisai, Ibaraki, Japan), anti-PD1 (anti-murine PD-1 mAb clone J43 BioXCell BE0033-2), combination therapy (lenvatinib plus anti-PD1) or placebo (drug vehicle plus polyclonal IgG, BioXCell BE0091) (Figure 1A).
Mice from the Hepa1-6 model were sacrificed at day 13 post-randomization (early timepoint, n=20), once tumor volume of 1000 mm 3 was reached or at study termination (late timepoint, n=39). The Hep53.4 model was used as validation and all animals were sacrificed at day 13 post-randomization. Tumor and blood samples were collected and processed for subsequent analyses (Figure 1A,2A). Assessment of the tumorigenic and histological features in an additional set of male and female mice (n=30) revealed no gender differences in our model (Supplementary Figure 1). Studies were performed in compliance with guidelines for the use of animals established by the institution ethical committee and the "Guide for the Care and Use of Laboratory Animals".

Torrens L., Montironi C., Puigvehí M., Mesropian A., Leslie J., Haber P.K., Maeda M., Balaseviciute U., Willoughby C.E., Abril-Fornaguera J., Piqué-Gili M., Torres-Martín M., Peix J., Geh D., Ramon-Gil E., Saberi B., Friedman S.L., Mann D.A., Sia D, & Llovet J.M. (2021). Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology (Baltimore, Md.), 74(5).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!